


METHODOLOGY ARTICLE

Open Access



Rapid and ultra-sensitive quantitation of disease-associated α -synuclein seeds in brain and cerebrospinal fluid by α Syn RT-QuIC

Bradley R. Groveman^{1†}, Christina D. Orrù^{1†}, Andrew G. Hughson¹, Lynne D. Raymond¹, Gianluigi Zanusso², Bernardino Ghetti³, Katrina J. Campbell¹, Jiri Safar⁴, Douglas Galasko^{5*} and Byron Caughey^{1*} 

Abstract

The diagnosis and treatment of synucleinopathies such as Parkinson disease and dementia with Lewy bodies would be aided by the availability of assays for the pathogenic disease-associated forms of α -synuclein (α Syn^D) that are sufficiently sensitive, specific, and practical for analysis of accessible diagnostic specimens. Two recent α Syn^D seed amplification tests have provided the first prototypes for ultrasensitive and specific detection of α Syn^D in patients' cerebrospinal fluid. These prototypic assays require 5–13 days to perform. Here, we describe an improved α -synuclein real time quaking-induced conversion (α Syn RT-QuIC) assay that has similar sensitivity and specificity to the prior assays, but can be performed in 1–2 days with quantitation. Blinded analysis of cerebrospinal fluid from 29 synucleinopathy cases [12 Parkinson's and 17 dementia with Lewy bodies] and 31 non-synucleinopathy controls, including 16 Alzheimer's cases, yielded 93% diagnostic sensitivity and 100% specificity for this test so far. End-point dilution analyses allowed quantitation of relative amounts of α Syn^D seeding activity in cerebrospinal fluid samples, and detection in as little as 0.2 μ L. These results confirm that α Syn^D seeding activity is present in cerebrospinal fluid. We also demonstrate that it can be rapidly detected, and quantitated, even in early symptomatic stages of synucleinopathy.

Keywords: Parkinson, Lewy body, Alzheimer, Diagnosis, Synuclein, Amplification, Cerebrospinal fluid, PMCA, RT-QuIC, Prion

Introduction

Many neurodegenerative diseases are related to the accumulation of specific misfolded proteins. These deposits are identified upon *post-mortem* analysis of brain tissue, allowing definite diagnoses to be made based on specific neuropathological and molecular findings. Less definitive *intra vitam* diagnoses can be proffered based on specific clinical signs, tissue imaging data, pathological examination of peripheral biopsies, and less-than-specific biomarker levels in the CSF. In particular, early diagnosis can be difficult and

discrimination between diseases can be complicated by clinical variability and overlaps in clinical features.

Parkinson's disease (PD), multiple system atrophy (MSA), dementia with Lewy bodies (DLB) [or Lewy body dementia] are called α -synucleinopathies due to the abnormal accumulation of aggregates of a protein called α -synuclein (α Syn) in the brain. Although the clinical diagnosis of parkinsonism can be relatively simple, the specific diagnosis of PD, especially at early stages, can be difficult. Adler et al. noted that in patients with possible PD (never treated or not clearly responsive to L-dopa) only 26% had autopsy confirmation as PD, while in probable PD (responsive to medications) the diagnostic accuracy was 82% [1]. In DLB, clinical diagnostic criteria for probable DLB predict α Syn pathology with sensitivity of about 80% [18] but early diagnosis of DLB is less accurate due to the overlapping symptoms with other types of dementia. In addition, in 15–20% of patients with Alzheimer disease (AD) at autopsy,

* Correspondence: dgalasko@ucsd.edu; bcaughey@nih.gov

[†]Equal contributors

⁵Department of Neurosciences, University of California-San Diego, La Jolla, CA, USA

¹Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA

Full list of author information is available at the end of the article



concomitant DLB pathology can be found, with only a minority of patients having exhibited clear diagnostic features of DLB [20, 34]. However, in patients with AD and diffuse Lewy body pathology, disease duration was shortened [11], indicating that DLB pathology contributes to dementia progression.

Some pertinent tests indirectly measure the effect of α -Syn pathology (e.g., dopamine receptor SPECT or PET scans, and MIBG cardiac scintigraphy), while the sensitivity and specificity of skin, salivary gland and colonic biopsy for PD or DLB has not been established in large scale studies. In these clinical settings of PD and DLB, the presence of a biomarker that indicates that abnormal pathological forms of a α Syn are present would improve diagnostic accuracy not only for prognostic purposes but also for cohort selection in disease-modifying clinical trials for PD. Attempts to determine if cerebrospinal fluid (CSF) levels of total, phosphorylated or oligomeric α -syn are diagnostically useful have been variable and controversial between studies [reviewed in [27]], and the diagnostic utility of immunoassays for these forms of α Syn in CSF remains unclear [21, 31].

However, two recent studies have provided evidence that analysis of a distinct feature of disease-associated forms of α Syn (hereafter abbreviated α Syn^D), namely their amyloid seeding activity, may have substantial diagnostic utility for PD and DLB [7, 35]. The rationale for the seeding activity assays is that the α Syn^D deposits contain fibrils, or subfibrillar oligomers, that propagate by a seeded polymerization mechanism in which α Syn^D templates, or seeds, conversion of non-fibrillar α Syn into larger oligomeric or aggregate, fibrillar forms. Mechanistically similar assays called Real-Time Quaking-Induced Conversion (RT-QuIC) have provided ultrasensitive, specific and quantitative diagnostic tests for prion diseases [2, 39]. RT-QuIC assays are multi-well plate-based reactions that can rapidly amplify oligomeric/multimeric prion seeds by as much as a trillion-fold [8, 24, 26, 39]. Prion RT-QuIC assays have been applied successfully to a variety of biological samples including brain [29, 39, 41], cerebrospinal fluid (CSF) [2, 5, 17, 24, 33], whole blood, plasma [26, 38], urine [14], and nasal brushings [23, 40]. They are being widely implemented for the diagnosis of prion diseases in humans and animals. Notably, our recent studies demonstrated provisional 100% diagnostic sensitivity and specificity in diagnosing human sporadic Creutzfeldt-Jakob disease using CSF and/or nasal swabs [4].

Green and colleagues adapted the RT-QuIC approach to synucleinopathies and applied it to a total of 137 PD and DLB cases and controls [7]. Their assay (α Syn RT-QuIC) has given 95 and 92% sensitivity for PD and DLB patients, respectively, with 100% specificity. Soto and colleagues developed a similar assay called α Syn protein misfolding

cyclic amplification (α Syn-PMCA) which gave 89% sensitivity for PD and 97% specificity in analyses of 173 total cases and controls [35]. In these assays, 5–40 μ l aliquots of CSF are added to reactions containing recombinant α Syn (α Syn). Any α Syn^D seeds in the sample initiate amyloid fibril formation by the recombinant α Syn which, in turn, enhances the fluorescence of thioflavin T (ThT). The reactions are performed over ~ 5 [7] to 13 days [35]. Sano and colleagues have described an α Syn RT-QuIC assay that detects DLB α Syn^D seeding activity in brain tissue at extreme dilutions in < 4 days [32]. Bernis and colleagues showed that 10% brain homogenate samples from mice inoculated with human MSA or incidental Lewy body disease brain tissue could seed fibrillization of α Syn in 1–2 days [3]. Here we report that by using a mutant α Syn substrate and optimized reaction conditions, α Syn RT-QuIC assays on CSF specimens can be completed within 1–2 days with high diagnostic sensitivity and specificity.

Materials and methods

Clinical assessment

All subjects provided consent to clinical assessment, including longitudinal follow-up, and to lumbar puncture to obtain CSF, under UCSD IRB-approved protocol #080012. All procedures performed in this study were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Some subjects died during the follow-up period, and had consented to their brains being obtained at autopsy.

All subjects underwent a detailed clinical research assessment, including review of outside medical records, history of cognitive and motor symptoms, mental state examination with the Mini-Mental State Exam or Montreal Cognitive Assessment, and detailed neuropsychological testing, structured physical neurological examination, including the Unified Parkinson's Disease Rating Scale (UPDRS) Part III motor examination. All subjects were enrolled in a research protocol that allowed annual follow-up reassessment and received at least one follow-up assessment after their baseline visit. Neuroimaging (MRI and in some instances FDG PET scan or DaTscan) results were reviewed when available. The research diagnoses were made by consensus of two neurologists who reviewed all of the available clinical information. Research diagnoses followed published criteria: controls had no history of major neurological or psychiatric illness and were normal on cognition and neurological examination; patients with AD met criteria for probable AD (NIA-AA 2011). For PD, criteria proposed by the Movement Disorder Society were used [30], and research guidelines were applied to diagnose PD-MCI [16], PD-dementia and DLB (possible and probable DLB were diagnosed according to McKeith [19]).

Lumbar puncture and CSF handling

Lumbar punctures (LPs) were performed in the early morning, after a fast of at least 8 h. Subjects were either sitting or lying, and LPs were performed with sterile technique using an atraumatic needle. CSF (15–20 mL) was withdrawn into a polypropylene tube and a sample was sent for analysis of cell count, total protein and glucose to a local laboratory. The remaining CSF was gently mixed, centrifuged at 1500 g for 10 min, then aliquotted in 500 μ L fractions into polypropylene cryotubes, flash frozen and stored at -80°C .

Autopsy brain analysis

Procedures at autopsy at the UCSD Alzheimer's Disease Research Center are as follows: the brain is divided sagittally and the left hemibrain is fixed in 10% buffered formalin while the right hemibrain is sectioned coronally and then frozen at -70°C in sealed plastic bags. Routinely, tissue blocks from the right hemibrain of the midfrontal, inferior parietal, and superior temporal cortices, primary visual cortex in the occipital cortex, hippocampus, basal ganglia, substantia nigra and cerebellum are removed and placed in 2% paraformaldehyde for subsequent thick sectioning by vibratome. Tissue blocks adjacent to the ones described above are stored at -70°C for subsequent immunoblot analysis for synaptic proteins and A β species (soluble and oligomers). Vibratome sections (40 μ m thick) are stored in cryoprotective medium at -20°C for subsequent immunochemical studies. The formalin-fixed left hemibrain is serially sectioned in 1 cm slices and tissue blocks from the regions described above are processed for histopathological examination by H&E, and Thioflavin-S (Thio-S) to detect tau and β -amyloid deposits. Lewy body pathology is evaluated using phosphorylated α -synuclein immunoreactivity with a mouse monoclonal antibody at 1:20,000 (BioLegend Cat# 825701 RRID:AB 2564891). Pathological diagnoses of AD and DLB are made using National Institute on Aging-Alzheimer's Association (NIA-AA) guidelines [22].

K23Q raSyn expression vector preparation

DNA sequences coding for human α -synuclein sequence (Accession No. NM_000345.3) amino acid residues 1–140 (wildtype) were amplified and ligated into the pET24 vector with an N-terminal His-tag (EMD Biosciences) and sequences were confirmed. The α -synuclein K23Q mutation [15] was engineered using Q5 Site-Directed Mutagenesis (NEB) using the primers CCACACCCTGTTGGGTTTCTCAG and CAGAAGCAGCAGGAAAGAC. The plasmids were transformed into BL21(DE3) *Escherichia coli* (EMD Biosciences).

raSyn protein purification

Five ml of LB media containing 50 μ g/mL kanamycin were inoculated from a glycerol stock of *E. coli* bacteria containing vectors either for wildtype (WT) or K23Q raSyn protein expression. Following 4–5-h incubation with continuous 225 rpm agitation at 37°C , 1 L of the auto-induction media [9] also containing 50 μ g/mL kanamycin was prepared and the 5 mL starter culture was added. The cells were grown in a shaking incubator at 37°C , 225 rpm, overnight. The next day cells were harvested by splitting the 1 L culture into four 250 ml conical tubes and centrifuging at $3273\times g$, 4°C , 10 min.

Cells were lysed using an osmotic shock protocol modified from Paslawski et al. [28]. Using a 25 mL serological pipette, the cell pellets were gently resuspended in 10% volume of room temperature osmotic shock buffer, (25 mL per 250 mL of cell culture before centrifugation) and incubated at room temperature for 10 min. The suspension was centrifuged at $9000\times g$, 20°C , 20 min. The supernatant was discarded and the pellet was gently resuspended in 10 mL of ice-cold water per pellet, using a 25 mL serological pipette. The cell suspensions were pooled into two 50 mL tubes to 20 ml each. 20 μ L of saturated MgCl_2 was added to each 20 mL suspension. The suspension was then mixed and incubated on ice with mild rocking for 3 min. Next, the suspension was centrifuged at $9000\times g$, 4°C , 30 min. The supernatant was collected in a 100 ml glass beaker that contained a stir bar for rapid continuous mixing while being careful not to incorporate air bubbles. The pH was reduced to pH 3.5 by adding a bolus of ~ 800 μ L 1 M HCl followed by additional 25 μ L increments as necessary while continuously monitoring the pH. A large amount of white precipitate was generated. The suspension was then incubated with gentle stirring at room temperature for 10 min, avoiding the formation of air bubbles. The tubes were centrifuged at $9000\times g$, 4°C , 30 min, and the supernatant was collected in a fresh 100 ml beaker using continuous agitation with a stir bar. The pH was adjusted to 7.5 with an ~ 800 μ L bolus of 1 M NaOH followed by 25 μ L increments as necessary. The protein extract was then filtered through a 0.45 μ m filter. Next, the extract was loaded onto a 5 ml Ni-NTA column (Qiagen) on an Äkta Pure chromatography system (GE) and washed with 20 mM Tris, pH 7.5 at room temperature. The column was further washed with 50 mM imidazole, 20 mM Tris, pH 7.5 which generated a peak that was not collected. A linear gradient up to 500 mM imidazole in 20 mM Tris, pH 7.5, was performed and a peak was collected between 150 and 375 mM imidazole (Additional file 1). This peak was then loaded onto a Q-HP column (GE) and washed with 20 mM Tris, pH 7.5. The column was further washed with 100 mM NaCl, 20 mM Tris, pH 7.5. A linear gradient up to 500 mM NaCl in 20 mM Tris pH 7.5 was performed and a peak was recovered between 300 and 350 mM NaCl. The protein was

filtered through a 0.22 μm filter and dialyzed against water overnight at 4 $^{\circ}\text{C}$ using a 3 kDa MWCO dialysis membrane. The next day, the protein was moved into fresh water for another 4 h dialysis. The protein concentration was determined with a UV–VIS spectrophotometer using a theoretical extinction coefficient at 280 nm of $0.36 (\text{mg}/\text{mL})^{-1} \text{cm}^{-1}$. The protein was lyophilized in aliquots and stored for a final concentration of $\sim 1.0 \text{ mg}/\text{ml}$ once resuspended in 500 μL of 40 mM phosphate buffer (pH 8.0). These aliquots were stored at -80°C until further use.

For comparative studies, human recombinant full-length (1–140 aa) WT αSyn was also purchased from Stratech, (Cambridge, UK).

Endotoxin concentration levels for αSyn protein purifications was determined using a ToxinSensor Endotoxin Detection kit (GenScript) according to manufacturer's protocol.

SDS-PAGE analysis

Samples were prepared in 2 \times sample loading buffer (final concentration: 62.5 mM Tris–HCl, pH 6.8, 5% glycerol, 3 mM EDTA, 5% SDS, 0.02% bromophenol blue, 4 M urea, 4% β -mercaptoethanol) and boiled for 5 min. Proteins were separated by gel electrophoresis using 10% Bis-TrisNuPAGE gels (Invitrogen). For total protein analysis, gels were stained with GelCode Blue Safe Protein Stain (Thermo Scientific, 24,594) according to the manufacturer's protocol.

Preparation of synthetic wildtype αSyn fibrils

A 100 μL solution of 1 mg/ml WT αSyn in PBS was subjected to continuous 1000 rpm shaking at 37 $^{\circ}\text{C}$ for 3 days in a 1.5 mL tube. The products were ThT-positive, indicating the presence of amyloid, and the OD_{280} and Western blot comparisons of supernatants before and after centrifugation indicated that $> 30\%$ of the total αSyn was insoluble and therefore aggregated.

Brain homogenate preparations

Brain homogenates (BH; 10% *w/v*) were prepared by homogenizing the tissue in PBS using a Bead Beater (Biospec Products; 11079110z) for 1 min at maximum speed. The homogenate was then spun at 2000 $\times g$ for 2 min at room temperature and the supernatant was transferred to a new tube and stored at -80°C for αSyn RT-QuIC analysis. For αSyn RT-QuIC testing, BHs were serially diluted in PBS.

αSyn RT-QuIC protocol

RT-QuIC reactions were performed in black 96-well plates with a clear bottom (Nalgene Nunc International). We preloaded plates with 6 glass or silica beads (1 mm in diameter, BioSpec Products or 0.8 mm, OPS Diagnostics, respectively) per well. Silica beads were ultimately chosen over the glass beads because of some occasional batch to batch variability that was observed with the glass beads. For brain homogenate seeded reactions, 2 μL of indicated

BH dilutions were added to wells containing 98 μL of the reaction mix to give final concentrations of 40 mM phosphate buffer (pH 8.0), 170 mM NaCl, 0.1 mg/ml of the designated αSyn (filtered through a 100 kD MWCO filter immediately prior to use), and 10 μM ThT. The plate was then sealed with a plate sealer film (Nalgene Nunc International) and incubated at 42 $^{\circ}\text{C}$ in a BMG FLUOstar Omega plate reader with cycles of 1 min shaking (400 rpm double orbital) and 1 min rest throughout the indicated incubation time. ThT fluorescence measurements (450 \pm 10 nm excitation and 480 \pm 10 nm emission; bottom read) were taken every 45 min. After the initial testing (data in Fig. 1) the fluorimeter gain settings were adjusted to maintain the fluorescence response within the readable range.

In the case of CSF seeded reactions, wells pre-loaded with 6 glass or silica beads were given 85 μL of a reaction mix adjusted to give final reaction concentrations of 40 mM phosphate buffer (pH 8.0), 170 mM NaCl, 0.1 mg/ml αSyn , 10 μM thioflavin T (ThT) and 0.0015% sodium dodecyl sulfate (SDS) and then 15 μL CSF, or dilutions thereof




Fig. 1 Detection of αSyn seeding activity in BH and CSF using K23Q (blue), WT (red) and WT* (green; commercial wild-type αSyn lacking a 6 \times histidine tag [7]) substrates. Reactions were seeded in quadruplicate with brain homogenate (BH) (top panel) or CSF (bottom panel) from Parkinson's disease (PD) or non-synucleinopathy (NS) including corticobasal degeneration cases (CBD BH) and healthy donors (NS CSF). For the BH assays, 10^{-3} (closed symbols) or 10^{-4} (open symbols) brain tissue dilutions from a single PD or NS case were used. For the CSF assays, 15 μL (undiluted) from two PD cases and one NS case was used. Each sample trace represents the average ThT signal of quadruplicate wells. For clarity only every other data point is plotted. The vertical dashed line designates the assay cutoff time used in subsequent analyses

in normal pooled CSF. The reaction plates were subjected to shake-rest cycles as for BH samples above and the reactions classified as RT-QuIC-positive or -negative based on criteria similar to those previously described for RT-QuIC analyses of brain specimens [23, 39]. Briefly, a ThT fluorescence threshold was calculated as the average fluorescence for all samples within the first 10 h of incubation, plus three Standard Deviations (SD). A sample was considered positive overall when at least two of four replicate wells crossed this calculated threshold. When only one of the quadruplicates crossed the threshold, the analysis was repeated.

Results

Rapid detection of α Syn^D by α Syn RT-QuIC

In developing our α Syn RT-QuIC, we focused primarily on a recombinant 6 \times histidine-tagged K23Q mutant of α Syn as a soluble α Syn substrate for α Syn^D-induced fibrillization. Recombinant K23Q α Syn was reported to fibrillize with kinetics similar to wild-type (WT) α Syn when seeded with preformed synthetic WT α Syn fibrils, but was slower to spontaneously fibrillize in the absence of preformed seeds [15]. This latter characteristic, we hypothesized, might improve the sensitivity of an α Syn RT-QuIC assay by enhancing the kinetic distinction between reactions seeded with samples from synucleinopathy cases versus controls. We iteratively optimized the K23Q purification protocol and α Syn RT-QuIC reaction conditions. The best purification protocol to date involves lysis by osmotic shock followed by acid precipitation and sequential metal-ion affinity and ion exchange chromatography steps [28]. No protein impurities were observed by SDS-PAGE analyses of our K23Q mutant α Syn, our similar preparation of a histidine-tagged WT α Syn, or a commercial wild-type α Syn preparation (without a 6 \times histidine tag) (WT*) that was used for the previously described α Syn RT-QuIC assay [7] (Additional file 1). However, because lipopolysaccharide (LPS) can contaminate bacterially derived protein preparations and might influence fibrillization, we assayed the three α Syn preparations and found that whereas our WT and K23Q α Syn preparations were negative for LPS in this assay (< 0.25 EU/ml), the WT* preparation had \geq 0.25 EU/ml LPS.

In the α Syn RT-QuIC assay itself, the sample volume, SDS concentration, temperature, bead size and number were particularly influential in improving the speed, sensitivity and specificity of the α Syn RT-QuIC assay for clinical samples (data not shown). Analyses of brain homogenates (BH) and CSF samples from a small initial set of synucleinopathy (PD and DLB) cases and non-synucleinopathy (NS) cases indicated that, whereas the NS brain and CSF specimens gave no positive RT-QuIC reactions above a threshold fluorescence (see [Materials and Methods](#)) over the 48-h reaction period, the PD and DLB samples gave positive responses within \sim 18–35 h for

BH and \sim 15–24 h for CSF (Figs. 1 and 2; Additional file 2). When prepared in this way, K23Q (Fig. 1, blue traces) and WT α Syn (red traces) gave similar responses to seeding with PD brain tissue (10^{-3} – 10^{-4} dilutions; Fig. 1A; Additional file 2) or CSF (15 μ l; Fig. 1B; Additional file 2) but the WT α Syn was more prone to give modest increases in ThT fluorescence in negative control reactions. The WT* α Syn (green traces), had slower responses and lower maximum ThT fluorescence readings when seeded with PD samples than our WT and K23Q α Syn substrate preparations. We do not know how the WT* α Syn was prepared, so either its preparation, its lack of 6 \times histidine tag, or LPS contamination might be responsible for its weaker responses to seeding compared to our preparations of WT and K23Q α Syn. With the more rapid PD-seeded reactions with our K23Q or WT α Syn substrates, we observed decreases in average ThT fluorescence after maximum fluorescence had been achieved. We have observed similar decreases in prion RT-QuIC reactions (e.g. [24]), but their cause has not been determined. Based on these data and the previously published work [15] we have used our K23Q mutant α Syn preparations in subsequent experiments.

Blinded analysis of CSF from synucleinopathy cases and controls

We performed blinded analyses of a larger set of CSF specimens obtained *antemortem* from synucleinopathy cases and




Fig. 2 Detection of α Syn seeding activity in BH (a) and CSF (b) from cases with DLB but not non-synucleinopathy cases using K23Q α Syn. Two μ l of 10^{-3} dilutions of DLB (red; $n = 3$) or CBD (gray; $n = 3$) BH, or 15 μ l (undiluted) CSF from DLB (red; $n = 3$) or healthy donors (NS CSF, gray; $n = 3$) were used per reaction. Each trace represents the average ThT signal of the four replicate wells

controls described in Table 1 and Additional file 3. AD cases ($n = 16$) were included as examples of a neurodegenerative protein misfolding disease that usually, but not always [10], lacks synucleinopathy. As such AD cases were analyzed as a separate category from NS samples. Other types of NS samples, including two progressive supranuclear palsy cases and one corticobasal degeneration case, were also included as controls. For many of the synucleinopathy (PD and DLB) cases, the CSF specimens were collected early in the overall clinical course of disease (Additional file 3). For 8 subjects with PD, the CSF was obtained while motor symptoms and signs were still too mild to warrant treatment with L-dopa or another drug with dopaminergic actions (de novo PD). The consensus diagnosis at follow-up or, if available, the autopsy diagnosis was used as the gold standard diagnosis. Final diagnoses of cases and controls based on 1 year or longer of clinical follow up after the LP, and/or autopsy examination of the brain, was thus used as the final diagnosis (Additional file 3). Two cases (13/020 and 14/045 in Additional file 3) were initially diagnosed with AD but with progression had recurring visual hallucinations that are the most robust of the clinical features that predict DLB. Thus, on follow-up, these cases were given diagnoses of possible DLB.

Almost all of the PD (11/12) and DLB (16/17) CSF samples, including those obtained from the two possible DLB cases, gave positive RT-QuIC responses within 15–35 h (Fig. 3). The average reaction time required to exceed our designated positivity threshold (see [Materials and Methods](#)) was similar for the PD and DLB specimens (Fig. 3c). Notably, most of the control cases without any clinical or neuropathological (when available) indication of synucleinopathy were negative in all 4 replicate α Syn RT-QuIC reactions. One case (15/044 in Additional file 3) with a diagnosis of primary progressive aphasia and frontotemporal dementia was positive in 1 of 4 replicate reactions in two independent assays (Fig. 3b; blue “x”). Although it did not meet our criterium of having ≥ 2 of 4 positive replicate reactions for an overall designation as a positive sample, this case might represent an atypical case of DLB with a clinical diagnosis of primary progressive aphasia [12] with marginally detectable amounts of α Syn^D in the CSF. No α Syn^D was detected by immunostaining in the midfrontal,

inferior parietal, and superior temporal cortices, primary visual cortex in the occipital cortex, hippocampus, basal ganglia, substantia nigra and cerebellum; however, this analysis did not include the amygdala, which can be an initial site of α Syn^D accumulation. Thus, while not meeting criteria to be considered positive for α Syn^D seed activity, we cannot rule out the presence of some α Syn^D pathology in this patient at this time.

Overall, the results from this blinded panel indicated diagnostic sensitivities, i.e. the percentage of cases giving positive RT-QuIC responses, of 93% for both PD and DLB. None of the non-synucleinopathy or AD controls met criteria to be considered positive RT-QuIC responses resulting in an apparent specificity of 100%.

Relative α Syn seeding activities in CSF and brain tissue from PD and DLB cases

To quantify the α Syn RT-QuIC seeding activities in samples from synucleinopathy cases, we performed end-point dilution analyses of frontal cortex brain tissue from representative PD ($n = 1$) and DLB ($n = 3$) cases and CSF samples from 5 DLB cases. All 4 brain samples indicated that positive reactions were obtained out to 10^{-5} – 10^{-6} dilutions of either the PD and DLB tissues (Fig. 4). Positive reactions were obtained from as little as 0.2 μ l CSF per reaction well in DLB cases (Fig. 4). Spearman-Kärber analyses [6] provided estimates of the concentrations of seeding activity units giving positive reactions in 50% of replicate reactions, i.e., the 50% “seeding doses” or SD_{50} s [39] (Fig. 4). The DLB and PD brain samples contained $\sim 10^5$ – 10^6 SD_{50} per mg of tissue while the CSF samples had 4–54 SD_{50} s per 15 μ l, i.e., our usual sample volume. The latter results indicated that these synucleinopathy CSF specimens had seeding activities that are substantially higher than the minimum detectable level of 1 SD_{50} . However, on a per weight basis, seeding activity in brain tissue appeared to be 10^4 – 10^5 -fold higher than the seeding activities measured in PD and DLB CSF specimens (Fig. 4). We note that slightly different conditions were used for the brain homogenate and CSF specimens because neither of the reaction conditions alone was well suited for detecting seeding activity in both types of samples. These

Table 1 Demographic data and cognitive impairment at the time of lumbar puncture (LP) in studied subjects

Final diagnosis	n	Age at onset (years)	Age at LP (years)	Mean interval between onset and LP (years)	Sex (M:F)	MMSE ^a
Dementia with Lewy Bodies	17	69.6 \pm 7.8	73.8 \pm 7.8	4.2	17:2	23.0 \pm 4.6
Parkinson's Disease	12	63.1 \pm 12.0	66.0 \pm 12.9	2.9	11:1	28.9 \pm 1.1
Alzheimer's Disease	16	69.9 \pm 9.1	73.9 \pm 9.1	4	12:4	22.9 \pm 3.3
Control ^b	12	n/a	71.3 \pm 7.0	n/a	4:8	28.8 \pm 1.2
Other ^b	3	65.7 \pm 11.4	67.7 \pm 10.7	2	2:1	20.5 \pm 8.1

^aMMSE: Mini-Mental State Examination, ^b“controls” and “others” were grouped into “non-synucleinopathies” for analysis




Fig. 3 Blinded testing of CSF samples by α -synuclein RT-QuIC. Samples from non-synucleinopathy (NS), Alzheimer’s disease (AD), dementia with Lewy bodies (DLB) or Parkinson’s disease (PD) patients, were tested blinded using the K23Q substrate. Quadruplicate reactions were seeded with 15 μ L of CSF. Each sample trace represents the average ThT signal of the four wells. Panel **a** shows the average fluorescence enhancement kinetics for the AD, DLB and PD patients over time along with the associated standard deviation at each time point. Data points in Panel **b** indicate the average fluorescence obtained for each individual case at 48 h. Bars show the average \pm SD for type of case. The dashed line shows the fluorescence threshold for a positive result. Data points in Panel **c** show the hours required for the average fluorescence to exceed the threshold for individual cases. Bars show the average \pm SD for type of case. The dashed line indicates the end of the reaction at 48-h. Blue x symbol indicates sample 15/044 which was tested twice and both times had only one well crossing fluorescence threshold out of the four replicates. This sample was considered negative, as it did not meet our criteria for overall sample positivity (see [Materials and Methods](#))




Fig. 4 End-point dilutions of synucleinopathy BH (**a**; sample # 081017) or CSF (**b**; sample # 10/005) samples by α Syn RT-QuIC. Each sample trace represents the average ThT signal of quadruplicate wells. Tables to the right of each graph indicate the concentration of SD₅₀ units calculated by Spearman-Kärber analysis for these, and additional, cases. End-point dilution experiments used for the additional calculated values shown in the upper and lower panels are provided in Additional files 4 and 5, respectively

different conditions, in addition to differences in absolute seed concentrations, seed characteristics, or sample matrix components, might have affected the relative seeding activities observed in brain and CSF specimens.

Analytical sensitivity using synthetic α Syn fibrils

Finally, to obtain an indication of the analytical sensitivity of our α Syn RT-QuIC, we prepared synthetic α Syn fibrils, spiked them into non-synucleinopathy CSF and assayed serial dilutions. As little as 100 ag of the synthetic fibril preparations gave at least 2/4 positive replicate reactions (Fig. 5), which was at least as sensitive analytically as the α Syn PMCA assay [35].

Discussion

The ability to detect α Syn^D as a causative pathological biomarker for synucleinopathies has important implications in diagnostics, the development of therapeutics, and fundamental studies of α Syn^D-based pathogenesis. Recent studies have demonstrated diagnostic utility for α Syn RT-QuIC and closely related α Syn PMCA assays using CSF specimens [7, 35]. Here we present an α Syn RT-QuIC assay with similar diagnostic accuracy but much reduced assay time, i.e. 1–2, rather than 5–13 days. Sano and colleagues detected α Syn seeding activity of DLB brain in 3–4 days [32], but as brain has much higher concentrations of α Syn^D seeding activity than CSF (Fig. 4), it is unclear how well their α Syn RT-QuIC assay would perform with CSF specimens. In any case, our reduced assay time markedly enhances the cost effectiveness and practicality of the α Syn RT-QuIC analyses of CSF. Most of the CSF specimens that we analyzed were collected relatively early in the disease

course of the given synucleinopathy. The early detection of α Syn^D is particularly helpful, firstly, because the accuracy of diagnoses based on other clinical indices is poorest in the earlier phases of disease, and, secondly, because the earlier the diagnosis, the earlier that any appropriately targeted therapies can be initiated before further tissue damage is done.

Improvements in the early diagnosis of synucleinopathies should also aid in the selection of suitable patients and controls for therapeutic trials. Furthermore, the ability to serially measure relative levels of α Syn^D in treated and untreated cohorts may provide an alternate means of monitoring the effects of treatments, especially those aimed at reducing the burden of α Syn^D in the brain. Here we have used end-point dilution analysis for quantitation by α Syn RT-QuIC, an approach that has been helpful in many studies using prion RT-QuIC [23, 24, 39]. A potential alternative approach to quantitation from RT-QuIC assays is the comparison of lag phases or times-to-threshold [13, 36] but further studies will be required to document its utility in α Syn RT-QuIC analyses of various specimen types.

Consistent with previous findings for α Syn PMCA [35], α Syn RT-QuIC is capable of detecting sub-femtogram amounts of α Syn fibrils that are orders of magnitude less than those required for more conventional assays such as Western blotting and ELISA, with typical detection limits for total levels of α Syn, in the ng and pg range, respectively. The α Syn RT-QuIC, however, detects only the forms of α Syn^D capable of seeding further α Syn misfolding. How our α Syn RT-QuIC sensitivity for synthetic α Syn amyloid seeds relates to its absolute sensitivity for any given form of α Syn^D in tissues is difficult to determine accurately because different forms of α Syn^D may have different seeding capacities per unit mass. Nonetheless, based on the average kinetics of seeding using PD or DLB CSF in Fig. 3, one might estimate femtogram levels of seeding capable α Syn^D may exist in the CSF of PD or DLB patient when compared to the synthetic α Syn amyloid seeding kinetics in Fig. 5. Furthermore, the difference in the average kinetics of seeding using PD or DLB CSF may be indicative of a “strain” difference, similar to what has been observed from CSF samples from different types of CJD cases in prion RT-QuIC reactions [8, 25]. While the difference in the average kinetics is statistically significant (Welch’s *t*-test, $p < 0.02$) between the two seed types, at this point we do not know the basis for this difference, or whether it might be diagnostically useful. It could be due to differences in average seed concentration or seed characteristics, such as potential structural differences between PD and DLB seeds, that contribute to kinetic differences in the α Syn RT-QuIC




Fig. 5 End-point dilutions of synthetic seeds spiked into CSF.

Synthetic α Syn fibrils were generated by continuous shaking at 1000 rpm at 37 °C for 3 days in a 1.5 mL tube containing 100 μ L of 1 mg/ml WT α Syn. Samples were monitored by ThT fluorescence. Following fibrilization the samples were spiked into non-synucleinopathy CSF and diluted in 10-fold serial dilutions. Each sample trace represents the average \pm SEM ThT signal of quadruplicate wells. For clarity, data points were plotted every fourth point and negative controls, which were all below the positivity threshold, are not displayed

responses. Testing of much higher numbers of PD and DLB samples is required to discern whether the difference in kinetics is maintained and if it is of diagnostic or mechanistic importance.

As our assay evolved, we saw evidence that several factors, such as sample volume, SDS concentration, temperature, and silica beads, strongly influenced the performance of the assay. However, at present we cannot be sure of the relative importance of these factors individually in allowing the assay to be substantially faster than previously described α Syn RT-QuIC or PMCA assays. Further testing will be necessary to better understand i) the breadth of synucleinopathies that are detected and/or discriminated by α Syn RT-QuIC assays, ii) the diagnostic sensitivities and specificities in clinical settings, iii) the extent to which levels of α Syn seeding activity in CSF or other diagnostic specimens correlates with disease prognosis, and iv) the relevance of α Syn^D seeding activity as a biomarker in therapeutic trials.

Conclusions

Compared to previously described α SynD seed amplification assays, the use of the α Syn substrate preparation, RT-QuIC reaction conditions, and end-point dilution assays that we describe here allowed for much more rapid detection and quantitation of α Syn seeding activity in CSF of patients with PD and DLB without reductions in diagnostic sensitivity or specificity.

Additional files

Additional file 1: Example of K23Q purification chromatograph, and total protein staining of collected fractions and of the commercial wild-type α Syn (WT^{*}), and our preparation of the WT and K23Q α Syn substrates. Absorbance spectra (blue) and buffer B gradients (green) for purification of K23Q using a Ni-NTA column (A and B) followed by a Q-HP column (C and D). Arrow in A denotes a peak representing contaminants. Dashed boxes in A and C denote the zoomed regions depicted in B and D. The * in C and D denote contaminants. The red vertical lines in B delineate the peak collected from the Ni-NTA column between 30 and 75% of buffer B1 (containing 100 and 350 mM imidazole, respectively) for further purification on the Q-HP column. The red lines in D indicate the peak collected from the Q-HP column between 30 and 35% of buffer B2 (containing 300 and 350 mM NaCl, respectively) to be used for dialysis and lyophilization. Panels E and F are a total protein Coomassie Blue staining of fractions collected from the Ni-NTA and Q-HP column, respectively. Panel G shows a comparative total protein Coomassie Blue staining of 2 μ g of the commercial wild-type α Syn (WT^{*}), and both of our WT and K23Q α Syn substrate preparations. The staining intensity and apparent molecular weight of the WT^{*} differs from our prepared WT and K23Q due to the lack of a poly-histidine tag [37], therefore a 5-fold higher amount of WT^{*} was run in panel H to investigate for potential contaminants with a higher intensity staining. (TIFF 5283 kb)

Additional file 2: Detection of α Syn seeding activity in BH and CSF using K23Q (blue), WT (red) and WT* (green; commercial wild-type α Syn lacking a 6x histidine tag [7]) substrates as described in Fig. 1 but with standard deviation. For clarity error bars are only displayed in one direction. (TIFF 1254 kb)

Additional file 3: Demographic and clinical information for subjects of this study. (XLSX 17 kb)

Additional file 4: α Syn RT-QuIC end-point dilution analysis of one Parkinson's (PD; 081017) and three dementia with Lewy bodies (DLB; 2004–16, 2006–005 and 2006–020) brain samples listed in Fig. 4. Reactions were seeded in quadruplicate with two μ l of either a 10^{-4} , 10^{-5} , 10^{-6} or a 10^{-7} brain homogenate (BH) dilutions. Each sample trace represents the average ThT signal of quadruplicate wells. (TIFF 852 kb)

Additional file 5: End-point dilutions by α Syn RT-QuIC of synucleinopathy CSF samples listed in Fig. 4. Each sample trace represents the average ThT signal of quadruplicate wells. Traces represent 15 (Blue), 7.5 (Red), 3.75 (Green), 1.89 (Purple), 0.94 (Orange), 0.47 (Black), 0.2 (Brown) and 0.1 (Dark Blue) μ l of DLBD CSF diluted into normal pooled CSF, when needed, to give overall CSF sample volumes of 15 μ l. (TIFF 1383 kb)

Acknowledgements

This work was supported in part by the Intramural Research Program of the NIAID, NIH (BC), NIH grant AG05131 (DG), the Parkinson's and Movement Disorder Foundation (BRG), the Shiley-Marcos Alzheimer's Disease Research Center at UCSD (DG), and PHS P30-AG010133 (BG). BRG, CDO, AGH and BC are inventors on a related U.S. Patent pending No. 62/567,079. The authors thank Dr. Daniel Otzen and Cagla Sahin, Aarhus University, Denmark for advice on purification, and Dr. Suzette Priola, Dr. Cathryn Haigh, and Michael Metrick for critical evaluation of this manuscript. We also thank Dr. Christina Sigurdson for establishing contact between BC and DG that made this project possible.

Authors' contributions

BC and DG oversaw the project. BRG, CO, LR and AH designed, performed, and helped interpret experiments. DG, GZ and BG provided clinical specimens. BC, BRG, CO, and DG drafted the initial manuscript. All authors read, helped to edit, and approved the final manuscript.

Competing interests

BRG, CO, AH, LR and BC are named as inventors on a US provisional patent application related to the technology described herein (see Acknowledgements). The other authors declare that they have no other competing interests.

Author details

¹Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA. ²Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. ³Indiana University School of Medicine, Indianapolis, IN, USA. ⁴Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA. ⁵Department of Neurosciences, University of California-San Diego, La Jolla, CA, USA.

Received: 16 January 2018 Accepted: 17 January 2018

Published online: 09 February 2018

References

- Adler CH, Beach TG, Hentz JG, Shill HA, Caviness JN, Driver-Dunckley E, Sabbagh MN, Sue LI, Jacobson SA, Belden CM et al (2014) Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. *Neurology* 83:406–412. <https://doi.org/10.1212/WNL.0000000000000641>
- Atarashi R, Satoh K, Sano K, Fuse Y, Yamaguchi N, Ishibashi D, Matsubara T, Nakagaki T, Yamanaka H, Shirabe S et al (2011) Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. *Nat Med* 17:175–178. <https://doi.org/10.1038/nm.2294>
- Bernis ME, Babila JT, Breid S, Wusten KA, Wullner U, Tamguney G (2015) Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein. *Acta Neuropathol Commun* 3:75. <https://doi.org/10.1186/s40478-015-0254-7>
- Bongianni M, Orrù CD, Groverman BR, Sacchetto L, Fiorini M, Tonoli G, Triva G, Capaldi S, Testi S, Ferrari S et al (2017) Diagnosis of human Prion disease using real-time quaking-induced conversion testing of olfactory mucosa and cerebrospinal fluid samples. *JAMA Neurology* 74:1–8
- Cramm M, Schmitz M, Karch A, Zafar S, Varges D, Mitrova E, Schroeder B, Raeber A, Kuhn F, Zerr I (2015) Characteristic CSF prion seeding efficiency in

- humans with prion diseases. *Mol Neurobiol* 51:396–405. <https://doi.org/10.1007/s12035-014-8709-6>
6. Dougherty RM (1964) Animal virus titration techniques. In: Harris RJC (ed) *Techniques in experimental virology*. Academic Press, Inc., City, pp 183–186
 7. Fairfoul G, McGuire LJ, Pal S, Ironside JW, Neumann J, Christie S, Joachim C, Esiri M, Evetts SG, Rolinski M et al (2016) Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. *Ann Clin Transl Neurol* 3:812–818. <https://doi.org/10.1002/acn3.338>
 8. Foutz A, Appleby BS, Hamlin C, Liu X, Yang S, Cohen Y, Chen W, Blevins J, Fausett C, Wang H et al (2017) Diagnostic and prognostic value of human prion detection in cerebrospinal fluid. *Ann Neurol* 81:79–92. <https://doi.org/10.1002/ana.24833>
 9. Fox BG, Blommel PG (2009) Autoinduction of protein expression. *Curr Protocols Protein Sci* 56:5.23.5.23.1–5.23.18. <https://doi.org/10.1002/0471140864.ps0523s56>
 10. Galvin JE, Lee VM, Trojanowski JQ (2001) Synucleinopathies: clinical and pathological implications. *Arch Neurol* 58:186–190
 11. Graff-Radford J, Aakre J, Savica R, Boeve B, Kremers WK, Ferman TJ, Jones DT, Kantarci K, Knopman DS, Dickson DW et al (2017) Duration and pathologic correlates of Lewy body disease. *JAMA Neurol* 74:310–315. <https://doi.org/10.1001/jamaneurol.2016.4926>
 12. Grossman M (2010) Primary progressive aphasia: clinicopathological correlations. *Nat Rev Neurol* 6:88–97. <https://doi.org/10.1038/nrneurol.2009.216>
 13. Henderson DM, Davenport KA, Haley NJ, Denkers ND, Mathiason CK, Hoover EA (2015) Quantitative assessment of prion infectivity in tissues and body fluids by real-time quaking-induced conversion. *J Gen Virol* 96:210–219. <https://doi.org/10.1099/vir.0.069906-0>
 14. John TR, Schatzl HM, Gilch S (2013) Early detection of chronic wasting disease prions in urine of pre-symptomatic deer by real-time quaking-induced conversion assay. *Prion* 7:253–258. <https://doi.org/10.4161/pri.24430>
 15. Koo HJ, Lee HJ, Im H (2008) Sequence determinants regulating fibrillation of human alpha-synuclein. *Biochem Biophys Res Commun* 368:772–778. <https://doi.org/10.1016/j.bbrc.2008.01.140>
 16. Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society task force guidelines. *Mov Disord* 27:349–356. <https://doi.org/10.1002/mds.24893>
 17. McGuire LJ, Peden AH, Orru CD, Wilham JM, Appleford NE, Mallinson G, Andrews M, Head MW, Caughey B, Will RG et al (2012) RT-QuIC analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. *Ann Neurol* 72:278–285
 18. McKeith IG, Ballard CG, Perry RH, Ince PG, O'Brien JT, Neill D, Lowery K, Jaros E, Barber R, Thompson P et al (2000) Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. *Neurology* 54:1050–1058
 19. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. *Neurology* 65:1863–1872. <https://doi.org/10.1212/01.wnl.0000187889.17253.b1>
 20. Merdes AR, Hansen LA, Jeste DV, Galasko D, Hofstetter CR, Ho GJ, Thal LJ, Corey-Bloom J (2003) Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. *Neurology* 60:1586–1590
 21. Mollenhauer B, Batrla R, El-Agnaf O, Galasko DR, Lashuel HA, Merchant KM, Shaw LM, Selkoe DJ, Umek R, Vanderstichele H et al (2017) A user's guide for alpha-synuclein biomarker studies in biological fluids: Perianalytical considerations. *Mov Disord*. <https://doi.org/10.1002/mds.27090>
 22. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS et al (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathol* 123:1–11. <https://doi.org/10.1007/s00401-011-0910-3>
 23. Orru CD, Bongianni M, Tonoli G, Ferrari S, Hughson AG, Groverman BR, Fiorini M, Pocchiarini M, Monaco S, Caughey B et al (2014) A test for Creutzfeldt-Jakob disease using nasal brushings. *New Engl J Med* 371:519–529
 24. Orru CD, Groverman BR, Hughson AG, Zanusso G, Coulthart MB, Caughey B (2015) Rapid and sensitive RT-QuIC detection of human Creutzfeldt-Jakob disease using cerebrospinal fluid. *MBio* 6. <https://doi.org/10.1128/mBio.02451-14>
 25. Orru CD, Groverman BR, Raymond LD, Hughson AG, Nonno R, Zou W, Ghetti B, Gambetti P, Caughey B (2015) Bank vole Prion protein as an apparently universal substrate for RT-QuIC-based detection and discrimination of Prion strains. *PLoS Path* 11:e1004983. <https://doi.org/10.1371/journal.ppat.1004983>
 26. Orru CD, Wilham JM, Raymond LD, Kuhn F, Schroeder B, Raeber AJ, Caughey B (2011) Prion disease blood test using immunoprecipitation and improved quaking-induced conversion. *mBio* 2:e00078–00011 doi: <https://doi.org/10.1128/mBio.00078-11>
 27. Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, El-Agnaf O, Calabresi P (2013) Cerebrospinal fluid biomarkers in Parkinson disease. *Nat Rev Neurol* 9:131–140. <https://doi.org/10.1038/nrneurol.2013.10>
 28. Paslawski W, Lorenzen N, Otzen DE (2016) Formation and characterization of alpha-Synuclein Oligomers. *Methods Mol Biol* 1345:133–150. https://doi.org/10.1007/978-1-4939-2978-8_9
 29. Peden AH, McGuire LJ, Appleford NE, Mallinson G, Wilham JM, Orru CD, Caughey B, Ironside JW, Knight RS, Will RG et al (2012) Sensitive and specific detection of sporadic Creutzfeldt-Jakob disease brain prion protein using real-time quaking induced conversion. *J Gen Virol* 93:438–449. <https://doi.org/10.1099/vir.0.033365-0>
 30. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE et al (2015) MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord* 30:1591–1601. <https://doi.org/10.1002/mds.26424>
 31. Sancesario GM, Bernardini S (2015) How many biomarkers to discriminate neurodegenerative dementia? *Crit Rev Clin Lab Sci* 52:314–326. <https://doi.org/10.3109/10408363.2015.1051658>
 32. Sano K, Atarashi R, Satoh K, Ishibashi D, Nakagaki T, Iwasaki Y, Yoshida M, Murayama S, Mishima K, Nishida N (2017) Prion-like seeding of Misfolded alpha-Synuclein in the brains of dementia with Lewy body patients in RT-QuIC. *Mol Neurobiol*. <https://doi.org/10.1007/s12035-017-0624-1>
 33. Sano K, Satoh K, Atarashi R, Takashima H, Iwasaki Y, Yoshida M, Sanjo N, Murai H, Mizusawa H, Schmitz M et al (2013) Early detection of abnormal prion protein in genetic human prion diseases now possible using real-time QuIC assay. *PLoS One* 8:e54915. <https://doi.org/10.1371/journal.pone.0054915>
 34. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA (2009) The neuropathology of probable Alzheimer disease and mild cognitive impairment. *Ann Neurol* 66:200–208. <https://doi.org/10.1002/ana.21706>
 35. Shahnawaz M, Tokuda T, Waragai M, Mendez N, Ishii R, Trenkwalder C, Mollenhauer B, Soto C (2017) Development of a biochemical diagnosis of Parkinson disease by detection of alpha-Synuclein Misfolded aggregates in cerebrospinal fluid. *JAMA Neurol* 74:163–172. <https://doi.org/10.1001/jamaneurol.2016.4547>
 36. Shi S, Mitteregger-Kretzschmar G, Giese A, Kretzschmar HA (2013) Establishing quantitative real-time quaking-induced conversion (qRT-QuIC) for highly sensitive detection and quantification of PrPSc in prion-infected tissues. *Acta Neuropathol Commun* 1:44. <https://doi.org/10.1186/2051-5960-1-44>
 37. Tal M, Silberstein A, Nusser E (1985) Why does Coomassie brilliant blue R interact differently with different proteins? A partial answer. *J Biol Chem* 260:9976–9980
 38. Vascellari S, Orru CD, Hughson AG, King D, Barron R, Wilham JM, Baron GS, Race B, Pani A, Caughey B (2012) Prion seeding activities of mouse scrapie strains with divergent PrPSc protease sensitivities and amyloid plaque content using RT-QuIC and eQuIC. *PLoS One* 7:e48969. <https://doi.org/10.1371/journal.pone.0048969>
 39. Wilham JM, Orru CD, Bessen RA, Atarashi R, Sano K, Race B, Meade-White KD, Taubner LM, Timmes A, Caughey B (2010) Rapid end-point Quantitation of Prion seeding activity with sensitivity comparable to bioassays. *PLoS Path* 6:e1001217. <https://doi.org/10.1371/journal.ppat.1001217>
 40. Zanusso G, Bongianni M, Caughey B (2014) A test for Creutzfeldt-Jakob disease using nasal brushings. *N Engl J Med* 371:1842–1843. <https://doi.org/10.1056/NEJMc1410732>
 41. Zanusso G, Monaco S, Pocchiarini M, Caughey B (2016) Advanced tests for early and accurate diagnosis of Creutzfeldt-Jakob disease. *Nat Rev Neurol* 12:325–333. <https://doi.org/10.1038/nrneurol.2016.65>